摘要
背景:近来科学尝试发现生物技术行业的新药,以治疗各种疾病,包括动脉粥样硬化。 目的:本研究的主要目的是突出与动脉粥样硬化斑块有关的细胞,分子生物学和炎症过程。 方法:对Pubmed,Google和Scopus数据库进行了全面的文献检索。 结果:动脉粥样硬化被认为是全球死亡的主要原因。动脉粥样硬化涉及生产活性氧(ROS)对细胞的氧化损伤。动脉壁动脉粥样硬化斑块的发展是常见的特征。在动脉粥样硬化中与动脉壁相关的特异性炎性标志物可用于诊断和治疗。这些包括一氧化氮(NO),细胞因子,巨噬细胞抑制因子(MIF),白细胞和Pselectin。涉及内皮祖细胞治疗,血管紧张素II型2(AT2R)和ATP激活的嘌呤能受体治疗的现代治疗范例值得注意。 结论:未来的药物可能被设计为针对AT2R的三种信号传导机制,它们是(a)激活蛋白质磷酸酶,导致蛋白质去磷酸化(b)通过血管扩张激活缓激肽/一氧化氮/环鸟嘌呤3'',5''-单磷酸途径c)刺激磷脂酶A(2)和花生四烯酸的释放。药物也可以被设计成对作用于心血管系统的ATP激活的嘌呤能受体通道型P2X7分子起作用。
关键词: 动脉粥样硬化,斑块,解剖结构,微结构,炎症,细胞,治疗。
图形摘要
Current Drug Targets
Title:The Molecular Concept of Atheromatous Plaques
Volume: 18 Issue: 11
关键词: 动脉粥样硬化,斑块,解剖结构,微结构,炎症,细胞,治疗。
摘要: Background: Recently, there are scientific attempts to discover new drugs in the biotechnology industry in order to treat various diseases including atherosclerosis.
Objective: The main objective of the present review was to highlight the cellular, molecular biology and inflammatory process related to the atheromatous plaques. Methods: A thorough literature search of Pubmed, Google and Scopus databases was done. Results: Atherosclerosis is considered to be a leading cause of death throughout the world. Atherosclerosis involves oxidative damage to the cells with production of reactive oxygen species (ROS). Development of atheromatous plaques in the arterial wall is a common feature. Specific inflammatory markers pertaining to the arterial wall in atherosclerosis may be useful for both diagnosis and treatment. These include Nitric oxide (NO), cytokines, macrophage inhibiting factor (MIF), leucocytes and Pselectin. Modern therapeutic paradigms involving endothelial progenitor cells therapy, angiotensin II type-2 (AT2R) and ATP-activated purinergic receptor therapy are notable to mention. Conclusion: Future drugs may be designed aiming three signalling mechanisms of AT2R which are (a) activation of protein phosphatases resulting in protein dephosphorylation (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway by vasodilation and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Drugs may also be designed to act on ATP-activated purinergic receptor channel type P2X7 molecules which acts on cardiovascular system.Export Options
About this article
Cite this article as:
The Molecular Concept of Atheromatous Plaques, Current Drug Targets 2017; 18 (11) . https://dx.doi.org/10.2174/1389450117666160502151600
DOI https://dx.doi.org/10.2174/1389450117666160502151600 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disease-Specific iPS Cell Models in Neuroscience
Current Molecular Medicine Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Impact of COVID-19 Infection on Maternal and Neonatal Outcomes: A Review of 11078 Pregnancies Reported in the Literature
Current Women`s Health Reviews Editorial (Thematic Issue: Therapeutic Interventions Against Trypanosomiasis)
Current Topics in Medicinal Chemistry Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Splice Modification to Restore Functional Dystrophin Synthesis in Duchenne Muscular Dystrophy
Current Pharmaceutical Design Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Identification of Important Positions within miRNAs by Integrating Sequential and Structural Features
Current Protein & Peptide Science Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Species Differences in Hepatocyte-Directed Gene Transfer: Implications for Clinical Translation
Current Gene Therapy Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery The Multiple Electrocardiographic Manifestations of Ventricular Repolarization Memory
Current Cardiology Reviews